AU756001B2 - Epiallopregnanolone in the treatment of CNS disorders - Google Patents
Epiallopregnanolone in the treatment of CNS disorders Download PDFInfo
- Publication number
- AU756001B2 AU756001B2 AU33292/99A AU3329299A AU756001B2 AU 756001 B2 AU756001 B2 AU 756001B2 AU 33292/99 A AU33292/99 A AU 33292/99A AU 3329299 A AU3329299 A AU 3329299A AU 756001 B2 AU756001 B2 AU 756001B2
- Authority
- AU
- Australia
- Prior art keywords
- hydroxy
- pregnan
- treatment
- prevention
- steroid induced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3786998A | 1998-03-11 | 1998-03-11 | |
| US09/037869 | 1998-03-11 | ||
| PCT/EP1999/001496 WO1999045931A1 (en) | 1998-03-11 | 1999-03-10 | Epiallopregnanolone in the treatment of cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3329299A AU3329299A (en) | 1999-09-27 |
| AU756001B2 true AU756001B2 (en) | 2003-01-02 |
Family
ID=21896803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU33292/99A Ceased AU756001B2 (en) | 1998-03-11 | 1999-03-10 | Epiallopregnanolone in the treatment of CNS disorders |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6455516B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1063999B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP3877961B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1270718C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE307592T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU756001B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2321728C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69927960T2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999045931A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
| DK1812009T3 (da) * | 2004-11-18 | 2013-08-05 | Umecrine Ab | GABA-steroidantagonister og deres anvendelse til behandling af CNS-lidelser |
| RU2413516C2 (ru) * | 2004-11-18 | 2011-03-10 | Умекрин Аб | Гамк-стероидные антагонисты и их применение в лечении нарушений цнс |
| DE102006003508A1 (de) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Arzneimittel umfassend eine Hormonkombination |
| DE102006003509A1 (de) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Kontrazeptivum |
| US20070203216A1 (en) * | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
| EP2711372A1 (en) | 2006-11-21 | 2014-03-26 | Umecrine AB | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders |
| EP2167098B1 (en) * | 2007-06-11 | 2018-09-05 | University Of Southern California | Allopregnanolone in a method for enhancing neurological function (alzheimer disease) |
| US20100204192A1 (en) | 2007-06-11 | 2010-08-12 | University Of Sourthern California | Agents, compositions and methods for enhancing neurological function |
| US20090048288A1 (en) * | 2007-08-13 | 2009-02-19 | H. Lundbeck A/S | Method of treating stress-mediated depression |
| JP5687287B2 (ja) * | 2010-01-14 | 2015-03-18 | ウメクライン ムード エービー | 改善された保存性及び溶解特性を有する3−ベータ−ヒドロキシ−5−アルファ−プレグナン−20−オンを含有する薬学的組成物 |
| CN106983754A (zh) | 2011-05-20 | 2017-07-28 | 国家医疗保健研究所 | Cb1受体拮抗剂 |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| RU2667065C2 (ru) | 2012-11-28 | 2018-09-14 | Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) | Производные прегненолона |
| US20150313915A1 (en) * | 2012-11-30 | 2015-11-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| CN106163528A (zh) | 2014-01-29 | 2016-11-23 | 梅克芳识别有限公司 | 用于治疗肝脑病的甾族化合物 |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) * | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI748936B (zh) | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ab公司 | 新穎化合物 |
| PH12018501923B1 (en) | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
| US10933014B2 (en) | 2017-01-09 | 2021-03-02 | Asarina Pharma Ab | Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof |
| CN110430883A (zh) | 2017-02-10 | 2019-11-08 | 阿沙里那制药公司 | 用于医学治疗的3β-羟基-5α-孕烷-20-酮 |
| WO2018147791A1 (en) | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor |
| US20210228596A1 (en) * | 2017-10-12 | 2021-07-29 | Sage Therapeutics, Inc. | Method of treating cns disorders with neurosteroids and gabaergic compounds |
| CN111918657A (zh) | 2018-04-05 | 2020-11-10 | 阿沙里那制药有限公司 | 用于治疗物质戒断障碍的gaba-a拮抗剂 |
| US20240383942A1 (en) | 2021-09-14 | 2024-11-21 | Nanjing Minova Pharmaceutical Co., Ltd. | Water-soluble allopregnanolone derivative, and preparation method therefor and use thereof |
| WO2023083980A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | Steroid as a modulator of gabaa receptor |
| WO2023083978A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor |
| WO2023083979A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995005826A1 (en) * | 1993-08-20 | 1995-03-02 | Jackson Meyer B | Method for regulating neuropeptide hormone secretion |
| AU7164798A (en) * | 1997-05-02 | 1998-11-27 | Wyeth | Pregnan-3-ol-20-ones |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| BR9509764A (pt) * | 1994-11-23 | 1998-07-07 | Cocensys Inc | Série androstano e pregnano para modulação alostérica de receptor de gaba |
-
1999
- 1999-03-10 CN CNB998060283A patent/CN1270718C/zh not_active Expired - Fee Related
- 1999-03-10 JP JP2000535346A patent/JP3877961B2/ja not_active Expired - Fee Related
- 1999-03-10 CA CA002321728A patent/CA2321728C/en not_active Expired - Fee Related
- 1999-03-10 WO PCT/EP1999/001496 patent/WO1999045931A1/en not_active Ceased
- 1999-03-10 EP EP99914491A patent/EP1063999B1/en not_active Expired - Lifetime
- 1999-03-10 DE DE69927960T patent/DE69927960T2/de not_active Expired - Lifetime
- 1999-03-10 AU AU33292/99A patent/AU756001B2/en not_active Ceased
- 1999-03-10 AT AT99914491T patent/ATE307592T1/de not_active IP Right Cessation
- 1999-03-11 US US09/266,035 patent/US6455516B1/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995005826A1 (en) * | 1993-08-20 | 1995-03-02 | Jackson Meyer B | Method for regulating neuropeptide hormone secretion |
| AU7164798A (en) * | 1997-05-02 | 1998-11-27 | Wyeth | Pregnan-3-ol-20-ones |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69927960T2 (de) | 2006-07-20 |
| WO1999045931A1 (en) | 1999-09-16 |
| EP1063999B1 (en) | 2005-10-26 |
| EP1063999A1 (en) | 2001-01-03 |
| CA2321728C (en) | 2008-12-09 |
| CN1270718C (zh) | 2006-08-23 |
| US6455516B1 (en) | 2002-09-24 |
| CN1300219A (zh) | 2001-06-20 |
| JP2002506034A (ja) | 2002-02-26 |
| AU3329299A (en) | 1999-09-27 |
| DE69927960D1 (de) | 2005-12-01 |
| ATE307592T1 (de) | 2005-11-15 |
| JP3877961B2 (ja) | 2007-02-07 |
| CA2321728A1 (en) | 1999-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2321728C (en) | Epiallopregnanolone in the treatment of cns disorders | |
| US8119619B2 (en) | Pregnane steroids and their use in the treatment of CNS disorders | |
| NZ618019A (en) | Antagonists of cb1 receptor. | |
| WO2009142594A9 (en) | The use of 3beta-ethenyl, methyl, 3alpha-hydroxy-steroids for the treatment of cns disorders | |
| US8372824B2 (en) | GABA-steroid antagonists and their use for the treatment of CNS disorders | |
| AU739146B2 (en) | Pregnan-3-ol-20-ones | |
| Bowers et al. | Biochemical and behavioral effects of steroids on GABAA receptor function in long-and short-sleep mice | |
| DE69126622T2 (de) | 2beta,19-methylenamin überbrückte steroide als aromatasehemmer | |
| JP2001513800A (ja) | 医薬組成物調製のためのピバガビンの使用 | |
| EP0538340A1 (en) | Therapeutic use of piperidine-2,6-diones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |